ZA200406276B - Controlled synthesis of ziprasidone and compositions thereof. - Google Patents

Controlled synthesis of ziprasidone and compositions thereof. Download PDF

Info

Publication number: ZA200406276B
Authority: ZA; South Africa
Prior art keywords: composition; indol; dihydro; ziprasidone; chloro
Prior art date: 2002-02-20

Application number

ZA200406276A

Other languages

English (en)

Inventor

Frank Robert Busch

Howard Harry Ralph Jr

Adam Worth Grobin

Kyle Robert Leeman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-20

Filing date

2004-08-05

Publication date

2005-09-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200406276(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-09-20 Publication of ZA200406276B publication Critical patent/ZA200406276B/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Liquid Crystal Substances (AREA)
Indole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pyridine Compounds (AREA)

ZA200406276A 2002-02-20 2004-08-05 Controlled synthesis of ziprasidone and compositions thereof. ZA200406276B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US35880602P	2002-02-20	2002-02-20
US35903802P	2002-02-21	2002-02-21
US36045902P	2002-02-27	2002-02-27

Publications (1)

Publication Number	Publication Date
ZA200406276B true ZA200406276B (en)	2005-09-20

Family

ID=27761437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200406276A ZA200406276B (en)	2002-02-20	2004-08-05	Controlled synthesis of ziprasidone and compositions thereof.

Country Status (41)

Country	Link
EP (1)	EP1476162B1 (no)
JP (1)	JP4554938B2 (no)
KR (1)	KR100773622B1 (no)
CN (2)	CN101735212A (no)
AP (1)	AP2004003103A0 (no)
AR (1)	AR038563A1 (no)
AT (1)	ATE359787T1 (no)
AU (2)	AU2003206035A1 (no)
BR (1)	BR0307833A (no)
CA (1)	CA2475302C (no)
CO (1)	CO5611138A2 (no)
CY (1)	CY1106467T1 (no)
DE (1)	DE60313289T2 (no)
DK (1)	DK1476162T3 (no)
EA (1)	EA007866B1 (no)
EC (1)	ECSP045239A (no)
ES (1)	ES2283745T3 (no)
GE (1)	GEP20074030B (no)
GT (1)	GT200300040A (no)
HR (1)	HRP20040711A2 (no)
IL (1)	IL163277A (no)
IS (1)	IS7344A (no)
MA (1)	MA27177A1 (no)
MX (1)	MXPA04006993A (no)
MY (1)	MY139523A (no)
NO (2)	NO20043902L (no)
NZ (1)	NZ534443A (no)
OA (1)	OA12774A (no)
PA (1)	PA8567001A1 (no)
PE (1)	PE20030942A1 (no)
PL (1)	PL372238A1 (no)
PT (1)	PT1476162E (no)
RS (1)	RS60404A (no)
SI (1)	SI1476162T1 (no)
SV (1)	SV2004001485A (no)
TN (1)	TNSN04159A1 (no)
TW (1)	TW200307546A (no)
UA (1)	UA77057C2 (no)
UY (1)	UY27668A1 (no)
WO (1)	WO2003070246A1 (no)
ZA (1)	ZA200406276B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1787984T3 (en)	2000-03-06	2017-01-30	Acadia Pharm Inc	AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES
BR0215429A (pt)	2001-12-28	2004-12-14	Acadia Pharm Inc	Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
US7253186B2 (en)	2002-06-24	2007-08-07	Carl-Magnus Andersson	N-substituted piperidine derivatives as serotonin receptor agents
AU2003247615B2 (en)	2002-06-24	2007-08-09	Acadia Pharmaceuticals Inc.	N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en)	2002-06-24	2009-05-26	Acadia Pharmaceuticals, Inc.	N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en)	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
SG170617A1 (en)	2003-01-16	2011-05-30	Acadia Pharm Inc	Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en)	2003-03-17	2004-12-02	Igor Rukhman	Polymorphs of valsartan
EP1618097A1 (en)	2003-04-21	2006-01-25	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
WO2005035531A1 (en)	2003-06-03	2005-04-21	Teva Paharmaceutical Industries Ltd.	POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
CA2543805A1 (en)	2003-10-24	2005-05-06	Gideon Pilarsky	Processes for preparation of ziprasidone
US20050197347A1 (en) *	2003-12-18	2005-09-08	Judith Aronhime	Polymorphic form B2 of ziprasidone base
WO2005085240A2 (en) *	2004-02-27	2005-09-15	Ranbaxy Laboratories Limited	Process for the preparation of ziprasidone
CA2467538C (en)	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en)	2004-05-21	2010-10-26	Acadia Pharmaceuticals, Inc.	Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en)	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en)	2004-09-27	2010-09-07	Acadia Pharmaceuticals, Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
AU2005289444B2 (en)	2004-09-27	2012-06-14	Acadia Pharmaceuticals Inc.	Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Procedimiento para la preparacion de ziprasidona.
EP1841764A1 (en) *	2005-01-27	2007-10-10	Hetero Drugs Limited	Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) *	2005-11-18	2007-05-19	Dipharma Spa	Procedimento per la preparazione di ziprasidone
CN100491375C (zh) *	2006-07-01	2009-05-27	浙江美诺华药物化学有限公司	一种齐拉西酮的制备方法
PL2134330T3 (pl)	2007-03-19	2013-10-31	Acadia Pharm Inc	Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
CN102234272A (zh) *	2010-04-21	2011-11-09	上海医药工业研究院	盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) *	2010-04-21	2015-08-05	上海医药工业研究院	甲磺酸齐拉西酮半水合物及其制备方法
PT3325444T (pt)	2015-07-20	2021-09-22	Acadia Pharm Inc	Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US10953000B2 (en)	2016-03-25	2021-03-23	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en)	2016-03-25	2017-09-28	Acadia Pharmaceuticals Inc.	Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en)	2016-12-20	2019-10-30	Acadia Pharmaceuticals Inc.	Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) *	2016-12-26	2018-07-03	四川科瑞德凯华制药有限公司	一种甲磺酸齐拉西酮的纯化及制备方法
EP3615028A1 (en)	2017-04-28	2020-03-04	Acadia Pharmaceuticals Inc.	Pimavanserin for treating impulse control disorder
EP3675827A1 (en)	2017-08-30	2020-07-08	Acadia Pharmaceuticals Inc.	Formulations of pimavanserin
CN112724066B (zh) *	2021-02-04	2022-10-21	海南鑫开源医药科技有限公司	一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) *	2023-01-17	2023-05-02	北京协和建昊医药技术开发有限责任公司	一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en)	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en)	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0874834B1 (en)	1995-11-07	2000-12-13	Pfizer Inc.	Processes and intermediates for preparing 3-(1-piperazinyl)-1,2-benzisothiazole
TW491847B (en) *	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
JP3102896B2 (ja)	1996-05-07	2000-10-23	ファイザーインク．	５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
IL127497A (en) *	1997-12-18	2002-07-25	Pfizer Prod Inc	Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en not_active Ceased
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active Expired - Fee Related
- 2003-02-17 EP EP03702918A patent/EP1476162B1/en not_active Revoked
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP4554938B2 (ja)	2010-09-29
NZ534443A (en)	2007-07-27
CA2475302C (en)	2009-05-12
HRP20040711A2 (en)	2004-12-31
SV2004001485A (es)	2004-05-07
GT200300040A (es)	2007-01-12
CN1635892A (zh)	2005-07-06
PT1476162E (pt)	2007-06-25
NO20100584L (no)	2004-09-17
ES2283745T3 (es)	2007-11-01
TW200307546A (en)	2003-12-16
UA77057C2 (en)	2006-10-16
PL372238A1 (en)	2005-07-11
BR0307833A (pt)	2004-12-07
WO2003070246A1 (en)	2003-08-28
TNSN04159A1 (fr)	2007-03-12
AR038563A1 (es)	2005-01-19
IS7344A (is)	2004-07-05
PA8567001A1 (es)	2003-12-10
EA007866B1 (ru)	2007-02-27
RS60404A (sr)	2006-10-27
EP1476162B1 (en)	2007-04-18
MA27177A1 (fr)	2005-01-03
EP1476162A1 (en)	2004-11-17
NO20043902L (no)	2004-09-17
MY139523A (en)	2009-10-30
CO5611138A2 (es)	2006-02-28
MXPA04006993A (es)	2004-11-10
EA200400815A1 (ru)	2004-12-30
AU2009202008A1 (en)	2009-06-11
CN101735212A (zh)	2010-06-16
CY1106467T1 (el)	2012-01-25
OA12774A (en)	2006-07-04
GEP20074030B (en)	2007-02-12
UY27668A1 (es)	2003-10-31
CA2475302A1 (en)	2003-08-28
IL163277A (en)	2010-05-31
ECSP045239A (es)	2004-09-28
PE20030942A1 (es)	2003-11-08
SI1476162T1 (sl)	2007-08-31
AP2004003103A0 (en)	2004-09-30
JP2005525347A (ja)	2005-08-25
DE60313289D1 (de)	2007-05-31
ATE359787T1 (de)	2007-05-15
DE60313289T2 (de)	2007-12-27
DK1476162T3 (da)	2007-07-02
KR20040086417A (ko)	2004-10-08
AU2003206035A1 (en)	2003-09-09
KR100773622B1 (ko)	2007-11-05

Publication	Publication Date	Title
CA2475302C (en)	2009-05-12	Controlled synthesis of ziprasidone and compositions thereof
US20040048876A1 (en)	2004-03-11	Ziprasidone composition and synthetic controls
IL227736A (en)	2017-07-31	Panthiazine salts and their use
WO2019243533A1 (en)	2019-12-26	Oga inhibitor compounds
JPH11504947A (ja)	1999-05-11	ドーパミンリセプタサブタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド
EP4125910B1 (en)	2025-11-12	Rho kinase inhibitors for treating frontotemporal dementia
EP3810594A1 (en)	2021-04-28	Oga inhibitor compounds
US20100063093A1 (en)	2010-03-11	Methods for the administration of iloperidone
EP3186257B1 (en)	2019-02-06	Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
IL293929A (en)	2022-08-01	Oga inhibitor compounds
KR20110074574A (ko)	2011-06-30	1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
MXPA99007112A (en)	2000-02-02	1-phenyl-4-benzylpiperazines:dopamine receptor subtype specific ligands (d4)